Healthcare Industry News: Pulse Oximetry
News Release - December 30, 2009
St. Vincent Hospital Renews Multi-Year, System-wide Contract for Masimo SET(R) Pulse Oximetry TechnologyIndianapolis-Based Health Provider Adds Six More Years to its Masimo SET Pulse Oximetry Standardization Contract
IRVINE, Calif., Dec. 30 (Healthcare Sales & Marketing Network) -- Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion Pulse Oximetry, announced today that St.Vincent Indianapolis Hospital has renewed its campus-wide contract for Masimo SET Pulse Oximetry technology. A Masimo customer since 2000, St.Vincent cites advanced monitoring technology, an upgradeable platform, and innovative new capabilities as key reasons for the six-year system-wide renewal of their technology standardization contract, which will continue to support the oximetry needs of the quaternary facility.
"All Pulse Oximetry technologies are not created equal," stated Kathy Gatons, BA, RRT, Director of Clinical Support at St.Vincent Hospital. "Masimo offers the best, most advanced oximetry technologies available. We know the measurements can be trusted and the alarms are valid when a Masimo pulse oximeter is on the patient. That's why we chose to standardize on Masimo SET 10 years ago and why we continue to leverage Masimo as our Pulse Oximetry platform for the future. Patient safety is a huge initiative that we support by placing Masimo technology at every patient bedside."
Continuing their standardization on Masimo SET Pulse Oximetry technology allows St.Vincent Hospital to leverage the unique breakthrough noninvasive blood constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry. Masimo Rainbow SET is the first-and-only technology platform capable of continuously and noninvasively measuring multiple blood constituents and parameters that previously required invasive procedures, including: total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI® for fluid responsiveness, and acoustic respiration rate (RRa™), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI). The ability to immediately detect and treat potentially life-threatening conditions without having to draw blood and wait for the results facilitates earlier and better clinical decisions that may help St.Vincent clinicians to save lives and improve patient outcomes.
According to Rex McKinney, MBA, RRT, CHP, FACHE, Executive Director, Clinical Support Services at St.Vincent Hospital, "Masimo has excelled at providing leading technology that we need to support our patient safety initiatives. St.Vincent places the highest priority on providing healthcare that is safe. The Masimo technology platform provides our clinicians with the tools to monitor patients effectively and provide the safest clinical setting possible."
Masimo Founder and CEO, Joe E. Kiani, stated, "As an early adopter of Masimo SET technology, St.Vincent was one of the first hospitals to see the clinical value and patient impact of Masimo technology. Today, their unwavering commitment to delivering the best possible patient outcomes and remaining on the front line of medical advances is as strong as ever. And, we are happy that they have chosen to bring the latest noninvasive technologies to the patients they serve with Masimo Rainbow SET - helping provide faster, more accurate diagnosis, treatment, and recovery to those in need."
St.Vincent Hospitals and Health Services
Driven by the faith of four Daughters of Charity who arrived in Indianapolis in 1881 with $34.77 in their pockets, the St.Vincent Hospital mission is to treat the poor and sick by following our Core Values of Service of the Poor, Reverence, Integrity, Wisdom, Creativity and Dedication. Our healthcare ministry has grown to include seven Centers of Excellence: Women's, Children's, Orthopedics, Cardiovascular, Neuroscience, Cancer Care and Bariatrics. The ageless mission of St.Vincent remains unchanged: to minister to the minds, bodies and spirits of those in need.
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that significantly improve patient care - helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low-Perfusion Pulse Oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased Pulse Oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET® Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Masimo Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at www.masimo.com.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results, risks related to our belief that Masimo SET and Masimo Rainbow SET will provide sufficient sensitivity and specificity to detect physiological abnormalities in real-time - enabling clinicians to detect and identify potentially life-threatening conditions earlier and make better clinical and treatment decisions that may help save lives and improve outcomes for their patients, risks related to our assumption that the system-wide renewal of St.Vincent Health Care will serve to substantially increase revenues, and risks related to our assumptions regarding the future of the St.Vincent Health Care system-wide Pulse Oximetry renewal contract, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87, Rad-57, Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.